Cell reports · 2021
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wheatley Adam K, Pymm Phillip, Esterbauer Robyn, Dietrich Melanie H, Lee Wen Shi, Drew Damien, Kelly Hannah G, Chan Li-Jin, Mordant Francesca L, Black Katrina A, Adair Amy, Tan Hyon-Xhi, Juno Jennifer A, Wragg Kathleen M, Amarasena Thakshila, Lopez Ester, Selva Kevin J, Haycroft Ebene R, Cooney James P, Venugopal Hariprasad, Tan Li Lynn, O Neill Matthew T, Allison Cody C, Cromer Deborah, Davenport Miles P, Bowen Richard A, Chung Amy W, Pellegrini Marc, Liddament Mark T, Glukhova Alisa, Subbarao Kanta, Kent Stephen J, Tham Wai-Hong
Аннотация
Potent neutralizing monoclonal antibodies are one of the few agents currently available to treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the viral spike protein can exhibit neutralization resistance, potentially affecting the effectiveness of some antibody-based therapeutics. Here, the generation of a diverse panel of 91 human, neutralizing monoclonal antibodies provides an in-depth structural and phenotypic definition of receptor binding domain (RBD) antigenic sites on the viral spike. These RBD antibodies ameliorate SARS-CoV-2 infection in mice and hamster models in a dose-dependent manner and in proportion to in vitro, neutralizing potency. Assessing the effect of mutations in the spike protein on antibody recognition and neutralization highlights both potent single antibodies and stereotypic classes of antibodies that are unaffected by currently circulating VOCs, such as B.1.351 and P.1. These neutralizing monoclonal antibodies and others that bind analogous epitopes represent potentially useful future anti-SARS-CoV-2 therapeutics.